AbelZeta Announces Two Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

ROCKVILLE, MD and SHANGHAI, China, November 22, 2023 - AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, announced today that two abstracts relating to its immuno-oncology drug development have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California, and online from December 9 to 12, 2023.